Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.

Tseng JH, Cowan RA, Afonso AM, Zhou Q, Iasonos A, Ali N, Thompson E, Sonoda Y, O'Cearbhaill RE, Chi DS, Abu-Rustum NR, Long Roche K.

Gynecol Oncol. 2018 Sep 2. pii: S0090-8258(18)31154-5. doi: 10.1016/j.ygyno.2018.08.024. [Epub ahead of print]

PMID:
30185381
2.

Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?

Tseng JH, Cowan RA, Zhou Q, Iasonos A, Byrne M, Polcino T, Polen-De C, Gardner GJ, Sonoda Y, Zivanovic O, Abu-Rustum NR, Long Roche K, Chi DS.

Gynecol Oncol. 2018 Aug 17. pii: S0090-8258(18)31131-4. doi: 10.1016/j.ygyno.2018.08.014. [Epub ahead of print]

PMID:
30126704
3.

A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.

LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C, Makker V, Hensley ML, Konner J, Grisham RN, Cangemi N, Soldan K, Spriggs DR, Sabbatini PJ, OʼCearbhaill RE.

Int J Gynecol Cancer. 2018 Jul;28(6):1176-1182. doi: 10.1097/IGC.0000000000001280.

PMID:
29757876
4.

Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study.

Oseledchyk A, Gennarelli RL, Leitao MM Jr, Aghajanian CA, Iasonos A, Zivanovic O, Zamarin D.

Cancer Med. 2018 Jun;7(6):2280-2287. doi: 10.1002/cam4.1447. Epub 2018 Apr 17.

5.

Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center.

Cowan RA, Tseng J, Ali N, Dearie H, Murthy V, Gennarelli RL, Iasonos A, Abu-Rustum NR, Chi DS, Long Roche KC, Brown CL.

Gynecol Oncol. 2018 Apr;149(1):43-48. doi: 10.1016/j.ygyno.2017.11.012.

PMID:
29605049
6.

International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers.

Mueller JJ, Lajer H, Mosgaard BJ, Bach Hamba S, Morice P, Gouy S, Hussein Y, Soslow RA, Schlappe BA, Zhou QC, Iasonos A, Høgdall C, Leary A, O'Cearbhaill RE, Abu-Rustum NR.

Int J Gynecol Cancer. 2018 Jun;28(5):915-924. doi: 10.1097/IGC.0000000000001263.

PMID:
29561302
7.

Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas.

Stathis A, Iasonos A, Seymour JF, Thieblemont C, Ribrag V, Zucca E, Younes A.

Clin Cancer Res. 2018 Jul 1;24(13):2993-2998. doi: 10.1158/1078-0432.CCR-17-3021. Epub 2018 Mar 13.

PMID:
29535129
8.

Prospective Comparative Study of Laparoscopic Narrow Band Imaging (NBI) Versus Standard Imaging in Gynecologic Oncology.

Aloisi A, Sonoda Y, Gardner GJ, Park KJ, Elliott SL, Zhou QC, Iasonos A, Abu-Rustum NR.

Ann Surg Oncol. 2018 Apr;25(4):984-990. doi: 10.1245/s10434-017-6314-4. Epub 2018 Jan 16.

PMID:
29340992
9.

Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.

Iasonos A, O'Quigley J.

J R Stat Soc Ser C Appl Stat. 2017 Nov;66(5):1015-1030. doi: 10.1111/rssc.12195. Epub 2016 Nov 7.

PMID:
29085158
10.

Time to publication of oncology trials and why some trials are never published.

Chapman PB, Liu NJ, Zhou Q, Iasonos A, Hanley S, Bosl GJ, Spriggs DR.

PLoS One. 2017 Sep 21;12(9):e0184025. doi: 10.1371/journal.pone.0184025. eCollection 2017.

11.

Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery.

Schiavone MB, Moukarzel L, Leong K, Zhou QC, Afonso AM, Iasonos A, Roche KL, Leitao MM Jr, Chi DS, Abu-Rustum NR, Zivanovic O.

Gynecol Oncol. 2017 Oct;147(1):115-119. doi: 10.1016/j.ygyno.2017.07.010. Epub 2017 Jul 19.

PMID:
28734498
12.

A reconstructed melanoma data set for evaluating differential treatment benefit according to biomarker subgroups.

Satagopan JM, Iasonos A, Kanik JG.

Data Brief. 2017 May 5;12:667-675. doi: 10.1016/j.dib.2017.05.005. eCollection 2017 Jun.

13.

Clinical Trials in the Genomic Era.

Joffe E, Iasonos A, Younes A.

J Clin Oncol. 2017 Mar 20;35(9):1011-1017. doi: 10.1200/JCO.2016.70.8891. Epub 2017 Feb 13. Review.

14.

A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.

Cowan RA, Eriksson AGZ, Jaber SM, Zhou Q, Iasonos A, Zivanovic O, Leitao MM Jr, Abu-Rustum NR, Chi DS, Gardner GJ.

Gynecol Oncol. 2017 May;145(2):230-235. doi: 10.1016/j.ygyno.2017.02.010. Epub 2017 Mar 9.

PMID:
28285846
15.

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM.

Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9.

PMID:
28281183
16.

Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping.

Schiavone MB, Scelzo C, Straight C, Zhou Q, Alektiar KM, Makker V, Soslow RA, Iasonos A, Leitao MM, Abu-Rustum NR.

Ann Surg Oncol. 2017 Jul;24(7):1965-1971. doi: 10.1245/s10434-017-5816-4. Epub 2017 Mar 3.

17.

Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale.

Satagopan JM, Iasonos A.

Contemp Clin Trials. 2017 Dec;63:40-50. doi: 10.1016/j.cct.2017.02.007. Epub 2017 Feb 22.

PMID:
28254404
18.

A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS.

Gynecol Oncol. 2017 Apr;145(1):27-31. doi: 10.1016/j.ygyno.2017.02.020. Epub 2017 Feb 14.

19.

An efficient basket trial design.

Cunanan KM, Iasonos A, Shen R, Begg CB, Gönen M.

Stat Med. 2017 May 10;36(10):1568-1579. doi: 10.1002/sim.7227. Epub 2017 Jan 18.

20.

Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.

Schram AM, Iasonos A, Hyman DM.

J Clin Oncol. 2016 Dec 20;34(36):4312-4314. Epub 2016 Oct 23. No abstract available.

21.

Early phase dose finding methodology.

Iasonos A, O'Quigley J.

Stat Med. 2017 Jan 30;36(2):201-203. doi: 10.1002/sim.7155. No abstract available.

PMID:
27921353
22.

Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency.

Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, Iasonos A.

J Clin Oncol. 2017 Jan 20;35(3):271-273. doi: 10.1200/JCO.2016.69.9751. Epub 2016 Nov 28. No abstract available.

23.

Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.

Mueller JJ, Kelly A, Zhou Q, Iasonos A, Long Roche K, Sonoda Y, O'Cearbhaill RE, Zivanovic O, Chi DS, Gardner GJ.

Gynecol Oncol. 2016 Dec;143(3):496-503. doi: 10.1016/j.ygyno.2016.09.014. Epub 2016 Sep 28.

24.

Dose expansion cohorts in Phase I trials.

Iasonos A, O'Quigley J.

Stat Biopharm Res. 2016;8(2):161-170. Epub 2016 Jun 2.

25.

Integrating the escalation and dose expansion studies into a unified Phase I clinical trial.

Iasonos A, O'Quigley J.

Contemp Clin Trials. 2016 Sep;50:124-34. doi: 10.1016/j.cct.2016.06.010. Epub 2016 Jul 5.

26.

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.

Iasonos A, Chapman PB, Satagopan JM.

Clin Cancer Res. 2016 May 1;22(9):2114-20. doi: 10.1158/1078-0432.CCR-15-2517. Review.

27.

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission.

O'Cearbhaill RE, Ragupathi G, Zhu J, Wan Q, Mironov S, Yang G, Spassova MK, Iasonos A, Kravetz S, Ouerfelli O, Spriggs DR, Danishefsky SJ, Sabbatini PJ.

Cancers (Basel). 2016 Apr 22;8(4). pii: E46. doi: 10.3390/cancers8040046.

28.

Dimension of model parameter space and operating characteristics in adaptive dose-finding studies.

Iasonos A, Wages NA, Conaway MR, Cheung K, Yuan Y, O'Quigley J.

Stat Med. 2016 Sep 20;35(21):3760-75. doi: 10.1002/sim.6966. Epub 2016 Apr 18.

29.

Measuring Toxicity in Phase I Clinical Trials--Letter.

Hyman DM, Eaton A, Ivy SP, Spriggs DR, Iasonos A.

Clin Cancer Res. 2016 Apr 1;22(7):1828. doi: 10.1158/1078-0432.CCR-15-3043. No abstract available.

30.

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.

Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM.

Cancer. 2016 Apr 15;122(8):1228-37. doi: 10.1002/cncr.29918. Epub 2016 Feb 24.

31.

Sequential monitoring of Phase I dose expansion cohorts.

Iasonos A, O'Quigley J.

Stat Med. 2017 Jan 30;36(2):204-214. doi: 10.1002/sim.6894. Epub 2016 Feb 7.

32.

An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.

Liang LW, Perez AR, Cangemi NA, Zhou Q, Iasonos A, Abu-Rustum N, Alektiar KM, Makker V.

Int J Gynecol Cancer. 2016 Mar;26(3):497-504. doi: 10.1097/IGC.0000000000000635.

33.

Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.

Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, Eriksson AG, Gardner GJ, Sonoda Y, Levine DA, Aghajanian C, Chi DS, Abu-Rustum NR, Zivanovic O.

Gynecol Oncol. 2016 Mar;140(3):436-42. doi: 10.1016/j.ygyno.2016.01.008. Epub 2016 Jan 9.

34.

Reply to M.P. Decatris et al.

Hyman DM, Solit DB, Iasonos A.

J Clin Oncol. 2016 Mar 10;34(8):887. doi: 10.1200/JCO.2015.65.2487. Epub 2016 Jan 11. No abstract available.

PMID:
26755514
35.

A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Bell-McGuinn KM, Konner JA, Tew WP, Hensley ML, Iasonos A, Charpentier E, Mironov S, Sabbatini P, Aghajanian C.

Int J Gynecol Cancer. 2016 Feb;26(2):255-60. doi: 10.1097/IGC.0000000000000591.

36.

Clinical trials: Early phase clinical trials-are dose expansion cohorts needed?

Iasonos A, O'Quigley J.

Nat Rev Clin Oncol. 2015 Nov;12(11):626-8. doi: 10.1038/nrclinonc.2015.174. Epub 2015 Oct 6. No abstract available.

37.

Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.

Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA.

Gynecol Oncol. 2015 Nov;139(2):236-41. doi: 10.1016/j.ygyno.2015.09.016. Epub 2015 Sep 25.

38.

Prognostic and Predictive Values and Statistical Interactions in the Era of Targeted Treatment.

Satagopan JM, Iasonos A, Zhou Q.

Genet Epidemiol. 2015 Nov;39(7):509-17. doi: 10.1002/gepi.21917. Epub 2015 Sep 9.

39.

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.

Eaton A, Iasonos A, Gounder MM, Pamer EG, Drilon A, Vulih D, Smith GL, Ivy SP, Spriggs DR, Hyman DM.

Clin Cancer Res. 2016 Feb 1;22(3):553-9. doi: 10.1158/1078-0432.CCR-15-0339. Epub 2015 Aug 31.

40.

Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping.

Schiavone MB, Zivanovic O, Zhou Q, Leitao MM Jr, Levine DA, Soslow RA, Alektiar KM, Makker V, Iasonos A, Abu-Rustum NR.

Ann Surg Oncol. 2016 Jan;23(1):196-202. doi: 10.1245/s10434-015-4612-2. Epub 2015 May 21.

41.

Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?

Iasonos A, Gönen M, Bosl GJ.

J Clin Oncol. 2015 Jul 1;33(19):2221-5. doi: 10.1200/JCO.2014.59.8466. Epub 2015 May 4. No abstract available.

42.

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.

Hyman DM, Eaton AA, Gounder MM, Pamer EG, Pettiford J, Carvajal RD, Ivy SP, Iasonos A, Spriggs DR.

Oncotarget. 2015 Aug 7;6(22):19316-27.

43.

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.

Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, Iasonos A, Spriggs DR, Bialer P, Lacouture ME, Teitcher JB, Katabi N, Fury MG.

Cancer Chemother Pharmacol. 2015 Apr;75(4):747-55. doi: 10.1007/s00280-015-2693-z. Epub 2015 Feb 12.

PMID:
25672916
44.

Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.

Suidan RS, Zhou Q, Iasonos A, O'Cearbhaill RE, Chi DS, Long Roche KC, Tanner EJ, Denesopolis J, Barakat RR, Zivanovic O.

Int J Gynecol Cancer. 2015 May;25(4):599-606. doi: 10.1097/IGC.0000000000000389.

45.

The role of systemic chemotherapy in the management of granulosa cell tumors.

Meisel JL, Hyman DM, Jotwani A, Zhou Q, Abu-Rustum NR, Iasonos A, Pike MC, Aghajanian C.

Gynecol Oncol. 2015 Mar;136(3):505-11. doi: 10.1016/j.ygyno.2014.12.026. Epub 2014 Dec 26.

46.

The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.

Meisel JL, Hyman DM, Garg K, Zhou Q, Dao F, Bisogna M, Gao J, Schultz ND, Grisham RN, Phillips M, Iasonos A, Kauff ND, Levine DA, Soslow RA, Spriggs DR.

Ann Oncol. 2014 Dec;25(12):2372-8. doi: 10.1093/annonc/mdu461. Epub 2014 Oct 3.

47.

Bridging Solutions in Dose Finding Problems.

O'Quigley J, Iasonos A.

Stat Biopharm Res. 2014 May 1;6(2):185-197.

48.

Reply to M. Voskoboynik et al.

Hyman DM, Eaton AA, Gounder MM, Ivy SP, Iasonos A, Spriggs DR.

J Clin Oncol. 2014 Oct 1;32(28):3199-200. doi: 10.1200/JCO.2014.56.5762. Epub 2014 Jul 28. No abstract available.

PMID:
25071117
49.

A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS.

Gynecol Oncol. 2014 Sep;134(3):455-61. doi: 10.1016/j.ygyno.2014.07.002. Epub 2014 Jul 11.

50.

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

Iasonos A, O'Quigley J.

J Clin Oncol. 2014 Aug 10;32(23):2505-11. doi: 10.1200/JCO.2013.54.6051. Epub 2014 Jun 30. Review.

Supplemental Content

Loading ...
Support Center